NTLX — Neurothera Labs Share Price
Last trade - 00:00- CA$16.98m
- CA$15.93m
- 46
- 23
- 60
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.04 | ||
| Price to Tang. Book | 19.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.44% | ||
| Return on Equity | -21.28% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurothera Labs Inc. is a Canada-based specialty clinical-stage pharmaceutical company. The Company is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in various drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation, and SCI- 210 for the treatment of ASD and status epilepticus.
Directors
- Last Annual
- January 31st, 2025
- Last Interim
- July 31st, 2025
- Incorporated
- January 18th, 2021
- Public Since
- July 19th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 84,900,000
- Address
- Suite 600, 890 West Pender Street, VANCOUVER, V6C 1J9
- Web
- Phone
- +1 6047287715
- Auditors
- DALE MATHESON CARR-HILTON LABONTE LLP
Similar to NTLX
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
MustGrow Biologics
TSX Venture Exchange
FAQ
As of Today at 12:16 UTC, shares in Neurothera Labs are trading at CA$0.20. This share price information is delayed by 15 minutes.
Shares in Neurothera Labs last closed at CA$0.20 and the price had moved by +33.33% over the past 365 days. In terms of relative price strength the Neurothera Labs share price has outperformed the Toronto Stock Exchange 300 Composite Index by +9.43% over the past year.
There is no consensus recommendation for this security.
Find out moreNeurothera Labs does not currently pay a dividend.
Neurothera Labs does not currently pay a dividend.
Neurothera Labs does not currently pay a dividend.
To buy shares in Neurothera Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.20, shares in Neurothera Labs had a market capitalisation of CA$16.98m.
Here are the trading details for Neurothera Labs:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NTLX
Based on an overall assessment of its quality, value and momentum Neurothera Labs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurothera Labs. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +14.56%.
As of the last closing price of CA$0.20, shares in Neurothera Labs were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neurothera Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Neurothera Labs' directors